ESMO 2022 | The rationale behind the ancillary study of the STAMPEDE AAP trial

Marina Parry, PhD, University College London, London, UK, provides the rationale behind conducting ancillary study of the Phase III STAMPEDE (NCT00268476) trial on the clinical qualification of transcriptome signatures for advanced prostate cancer starting androgen deprivation therapy with or without abiraterone acetate and prednisolone. The trial found abiraterone to be effective at prolonging overall-survival (OS) in patients, however, the outcomes were variable. The ancillary study was conducted to evaluate the use of transcriptomics to classify patients and provide information on why certain patients fair better than others. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.